C2orf42

Across TCGA pan-cancer cohorts, C2orf42 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C2orf42 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher C2orf42 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated C2orf42 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, LSCC, and PDAC are the cancer types where C2orf42 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.163	0.701	.001	27	view →
LSCC	DFS	Median	II,III,IV	0.852	0.561	.007	24	view →
PDAC	DFS	Tertile	All	0.450	1.000	.016	16	view →
HNSC	DFS	Median	IV	0.862	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C2orf42–GBM (OS)

Open the GBM breakdown →